Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.94 |
---|---|
High | 5.14 |
Low | 4.61 |
Bid | 4.75 |
Offer | 5.10 |
Previous close | 4.90 |
Average volume | 459.59k |
---|---|
Shares outstanding | 19.32m |
Free float | 9.37m |
P/E (TTM) | -- |
Market cap | 94.67m USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
More ▼